Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

10.53EUR
29 Jul 2016
Change (% chg)

€-0.04 (-0.38%)
Prev Close
€10.57
Open
€10.70
Day's High
€10.70
Day's Low
€10.45
Volume
55,540
Avg. Vol
249,202
52-wk High
€15.19
52-wk Low
€8.26

IPH.PA

Chart for IPH.PA

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.22
Market Cap(Mil.): €569.89
Shares Outstanding(Mil.): 53.92
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 42.74 36.62
EPS (TTM): -0.13 -- --
ROI: -4.12 -9.63 14.52
ROE: -9.14 -9.94 15.68

BRIEF-Phase I study protocol investigating Innate Pharma's IPH4102

* Announced on Sunday that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris discussed the protocol of the ongoing first in human study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas (CTCL)

Jun 06 2016

BRIEF-Innate Pharma Q1 revenue jumps to 5.7 million euros

* Q1 revenue EUR 5.7 million versus EUR 0.4 million year ago

May 04 2016

BRIEF-Innate Pharma and Orega Biotech present preclinical data on IPH52

* Innate Pharma and Orega Biotech presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program

Apr 19 2016

BRIEF-Innate Pharma presents new preclinical data supporting development of IPH4301

* New preclinical data further supporting development of IPH4301 presented at AACR meeting

Apr 18 2016

BRIEF-Innate Pharma displays broad innovative pipeline in immuno-oncology

* AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology

Mar 17 2016

BRIEF-Innate Pharma FY net loss narrows to 6.7 million euros 

* FY revenue and other income amounts to 25.1 million euros ($27.98 million) versus 7.6 million euros in 2014

Feb 18 2016

BRIEF-Innate Pharma to start phase I clinical trial of monalizumab

* Announces the start of phase I clinical trial of monalizumab in combination with durvalumab

Feb 08 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.